These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1319983)

  • 1. 32P-postlabeling analysis of DNA adducts in rats during estrogen-induced hepatocarcinogenesis and effect of tamoxifen on DNA adduct level.
    Shimomura M; Higashi S; Mizumoto R
    Jpn J Cancer Res; 1992 May; 83(5):438-44. PubMed ID: 1319983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of alcohol ingestion on carcinogenesis by synthetic estrogen and progestin in the rat liver.
    Yamagiwa K; Higashi S; Mizumoto R
    Jpn J Cancer Res; 1991 Jul; 82(7):771-8. PubMed ID: 1679055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite.
    Randerath K; Moorthy B; Mabon N; Sriram P
    Carcinogenesis; 1994 Oct; 15(10):2087-94. PubMed ID: 7955037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alcohol ingestion enhances hepatocarcinogenesis induced by synthetic estrogen and progestin in the rat.
    Yamagiwa K; Mizumoto R; Higashi S; Kato H; Tomida T; Uehara S; Tanigawa K; Tanaka M; Ishida N
    Cancer Detect Prev; 1994; 18(2):103-14. PubMed ID: 8025892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling.
    Divi RL; Osborne MR; Hewer A; Phillips DH; Poirier MC
    Cancer Res; 1999 Oct; 59(19):4829-33. PubMed ID: 10519392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of activation of ornithine decarboxylase and DNA synthesis on ethynylestradiol-induced hepatocarcinogenesis.
    Machishi H; Higashi S; Hibasami H; Nakashima K; Kawarada Y; Mizumoto R
    Carcinogenesis; 1995 Dec; 16(12):2965-71. PubMed ID: 8603471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus.
    Li D; Dragan Y; Jordan VC; Wang M; Pitot HC
    Cancer Res; 1997 Apr; 57(8):1438-41. PubMed ID: 9108442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen.
    Pathak DN; Pongracz K; Bodell WJ
    Carcinogenesis; 1995 Jan; 16(1):11-5. PubMed ID: 7834794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Synthetic female hormones-induced liver cancer].
    Azuma T; Mizumoto R
    Gan No Rinsho; 1989 May; Spec No():54-61. PubMed ID: 2557462
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mechanisms of estrogen-induced carcinogenesis--detection of DNA adducts in cultured mammalian cells by 32P-postlabeling].
    Tsutsui T
    Nihon Yakurigaku Zasshi; 1997 Jul; 110(1):1-9. PubMed ID: 9285831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of a DNA adduct detectable by 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17 beta and testosterone.
    Han X; Liehr JG; Bosland MC
    Carcinogenesis; 1995 Apr; 16(4):951-4. PubMed ID: 7728979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen.
    Divi RL; Dragan YP; Pitot HC; Poirier MC
    Carcinogenesis; 2001 Oct; 22(10):1693-9. PubMed ID: 11577011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats.
    Hard GC; Iatropoulos MJ; Jordan K; Radi L; Kaltenberg OP; Imondi AR; Williams GM
    Cancer Res; 1993 Oct; 53(19):4534-41. PubMed ID: 8402624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen.
    Shibutani S; Suzuki N; Laxmi YR; Schild LJ; Divi RL; Grollman AP; Poirier MC
    Cancer Res; 2003 Aug; 63(15):4402-6. PubMed ID: 12907611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrospray ionization-tandem mass spectrometry and 32P-postlabeling analyses of tamoxifen-DNA adducts in humans.
    Beland FA; Churchwell MI; Doerge DR; Parkin DR; Malejka-Giganti D; Hewer A; Phillips DH; Carmichael PL; Gamboa da Costa G; Marques MM
    J Natl Cancer Inst; 2004 Jul; 96(14):1099-104. PubMed ID: 15265972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA adduct formation in liver and kidney of male Syrian hamsters treated with estrogen and/or alpha-naphthoflavone.
    Liehr JG; Gladek A; Macatee T; Randerath E; Randerath K
    Carcinogenesis; 1991 Mar; 12(3):385-9. PubMed ID: 2009585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic estrogens and tamoxifen as promoters of hepatocarcinogenesis.
    Yager JD; Shi YE
    Prev Med; 1991 Jan; 20(1):27-37. PubMed ID: 1672563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells.
    White IN; de Matteis F; Davies A; Smith LL; Crofton-Sleigh C; Venitt S; Hewer A; Phillips DH
    Carcinogenesis; 1992 Dec; 13(12):2197-203. PubMed ID: 1473224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of DNA by mitomycin C in cancer patients detected by 32P-postlabeling analysis.
    Kato S; Yamashita K; Kim T; Tajiri T; Onda M; Sato S
    Mutat Res; 1988 Nov; 202(1):85-91. PubMed ID: 2847037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cumulative exposure to tamoxifen: DNA adducts and liver cancer in the rat.
    Carthew P; Lee PN; Edwards RE; Heydon RT; Nolan BM; Martin EA
    Arch Toxicol; 2001 Aug; 75(6):375-80. PubMed ID: 11570696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.